Copyright Reports & Markets. All rights reserved.

Global Favipiravir API Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Favipiravir API Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Purity ≥ 98%
    • 1.3.3 Purity < 98%
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Favipiravir API Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Pharmaceuticals
    • 1.4.3 Scientific Research
    • 1.4.4 Others
  • 1.5 Global Favipiravir API Market Size & Forecast
    • 1.5.1 Global Favipiravir API Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Favipiravir API Sales Quantity (2021-2032)
    • 1.5.3 Global Favipiravir API Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Chunghwa Chemical Synthesis & Biotech
    • 2.1.1 Chunghwa Chemical Synthesis & Biotech Details
    • 2.1.2 Chunghwa Chemical Synthesis & Biotech Major Business
    • 2.1.3 Chunghwa Chemical Synthesis & Biotech Favipiravir API Product and Services
    • 2.1.4 Chunghwa Chemical Synthesis & Biotech Favipiravir API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Chunghwa Chemical Synthesis & Biotech Recent Developments/Updates
  • 2.2 TODACO
    • 2.2.1 TODACO Details
    • 2.2.2 TODACO Major Business
    • 2.2.3 TODACO Favipiravir API Product and Services
    • 2.2.4 TODACO Favipiravir API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 TODACO Recent Developments/Updates
  • 2.3 Tagoor Laboratories
    • 2.3.1 Tagoor Laboratories Details
    • 2.3.2 Tagoor Laboratories Major Business
    • 2.3.3 Tagoor Laboratories Favipiravir API Product and Services
    • 2.3.4 Tagoor Laboratories Favipiravir API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Tagoor Laboratories Recent Developments/Updates
  • 2.4 Biophore
    • 2.4.1 Biophore Details
    • 2.4.2 Biophore Major Business
    • 2.4.3 Biophore Favipiravir API Product and Services
    • 2.4.4 Biophore Favipiravir API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Biophore Recent Developments/Updates
  • 2.5 Lee Pharma
    • 2.5.1 Lee Pharma Details
    • 2.5.2 Lee Pharma Major Business
    • 2.5.3 Lee Pharma Favipiravir API Product and Services
    • 2.5.4 Lee Pharma Favipiravir API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Lee Pharma Recent Developments/Updates
  • 2.6 Forewin Pharma
    • 2.6.1 Forewin Pharma Details
    • 2.6.2 Forewin Pharma Major Business
    • 2.6.3 Forewin Pharma Favipiravir API Product and Services
    • 2.6.4 Forewin Pharma Favipiravir API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Forewin Pharma Recent Developments/Updates
  • 2.7 Senova Technology
    • 2.7.1 Senova Technology Details
    • 2.7.2 Senova Technology Major Business
    • 2.7.3 Senova Technology Favipiravir API Product and Services
    • 2.7.4 Senova Technology Favipiravir API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Senova Technology Recent Developments/Updates
  • 2.8 Zhejiang Hengkang Pharmaceutical
    • 2.8.1 Zhejiang Hengkang Pharmaceutical Details
    • 2.8.2 Zhejiang Hengkang Pharmaceutical Major Business
    • 2.8.3 Zhejiang Hengkang Pharmaceutical Favipiravir API Product and Services
    • 2.8.4 Zhejiang Hengkang Pharmaceutical Favipiravir API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Zhejiang Hengkang Pharmaceutical Recent Developments/Updates
  • 2.9 Maithili Life Sciences
    • 2.9.1 Maithili Life Sciences Details
    • 2.9.2 Maithili Life Sciences Major Business
    • 2.9.3 Maithili Life Sciences Favipiravir API Product and Services
    • 2.9.4 Maithili Life Sciences Favipiravir API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Maithili Life Sciences Recent Developments/Updates
  • 2.10 Hangzhou HETA Pharm & Chem
    • 2.10.1 Hangzhou HETA Pharm & Chem Details
    • 2.10.2 Hangzhou HETA Pharm & Chem Major Business
    • 2.10.3 Hangzhou HETA Pharm & Chem Favipiravir API Product and Services
    • 2.10.4 Hangzhou HETA Pharm & Chem Favipiravir API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Hangzhou HETA Pharm & Chem Recent Developments/Updates
  • 2.11 Aurore Life Sciences
    • 2.11.1 Aurore Life Sciences Details
    • 2.11.2 Aurore Life Sciences Major Business
    • 2.11.3 Aurore Life Sciences Favipiravir API Product and Services
    • 2.11.4 Aurore Life Sciences Favipiravir API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Aurore Life Sciences Recent Developments/Updates
  • 2.12 Bajaj Healthcare
    • 2.12.1 Bajaj Healthcare Details
    • 2.12.2 Bajaj Healthcare Major Business
    • 2.12.3 Bajaj Healthcare Favipiravir API Product and Services
    • 2.12.4 Bajaj Healthcare Favipiravir API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Bajaj Healthcare Recent Developments/Updates

3 Competitive Environment: Favipiravir API by Manufacturer

  • 3.1 Global Favipiravir API Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Favipiravir API Revenue by Manufacturer (2021-2026)
  • 3.3 Global Favipiravir API Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Favipiravir API by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Favipiravir API Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Favipiravir API Manufacturer Market Share in 2025
  • 3.5 Favipiravir API Market: Overall Company Footprint Analysis
    • 3.5.1 Favipiravir API Market: Region Footprint
    • 3.5.2 Favipiravir API Market: Company Product Type Footprint
    • 3.5.3 Favipiravir API Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Favipiravir API Market Size by Region
    • 4.1.1 Global Favipiravir API Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Favipiravir API Consumption Value by Region (2021-2032)
    • 4.1.3 Global Favipiravir API Average Price by Region (2021-2032)
  • 4.2 North America Favipiravir API Consumption Value (2021-2032)
  • 4.3 Europe Favipiravir API Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Favipiravir API Consumption Value (2021-2032)
  • 4.5 South America Favipiravir API Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Favipiravir API Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Favipiravir API Sales Quantity by Type (2021-2032)
  • 5.2 Global Favipiravir API Consumption Value by Type (2021-2032)
  • 5.3 Global Favipiravir API Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Favipiravir API Sales Quantity by Application (2021-2032)
  • 6.2 Global Favipiravir API Consumption Value by Application (2021-2032)
  • 6.3 Global Favipiravir API Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Favipiravir API Sales Quantity by Type (2021-2032)
  • 7.2 North America Favipiravir API Sales Quantity by Application (2021-2032)
  • 7.3 North America Favipiravir API Market Size by Country
    • 7.3.1 North America Favipiravir API Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Favipiravir API Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Favipiravir API Sales Quantity by Type (2021-2032)
  • 8.2 Europe Favipiravir API Sales Quantity by Application (2021-2032)
  • 8.3 Europe Favipiravir API Market Size by Country
    • 8.3.1 Europe Favipiravir API Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Favipiravir API Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Favipiravir API Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Favipiravir API Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Favipiravir API Market Size by Region
    • 9.3.1 Asia-Pacific Favipiravir API Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Favipiravir API Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Favipiravir API Sales Quantity by Type (2021-2032)
  • 10.2 South America Favipiravir API Sales Quantity by Application (2021-2032)
  • 10.3 South America Favipiravir API Market Size by Country
    • 10.3.1 South America Favipiravir API Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Favipiravir API Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Favipiravir API Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Favipiravir API Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Favipiravir API Market Size by Country
    • 11.3.1 Middle East & Africa Favipiravir API Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Favipiravir API Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Favipiravir API Market Drivers
  • 12.2 Favipiravir API Market Restraints
  • 12.3 Favipiravir API Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Favipiravir API and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Favipiravir API
  • 13.3 Favipiravir API Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Favipiravir API Typical Distributors
  • 14.3 Favipiravir API Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Favipiravir API market size was valued at US$ 1709 million in 2025 and is forecast to a readjusted size of US$ 2301 million by 2032 with a CAGR of 4.4% during review period.
    Favipiravir API is a broad-spectrum antiviral drug with the chemical name 6-fluoro-3-hydroxy-pyrazine-2-carboxamide. It acts on the viral RNA-dependent RNA polymerase, accelerating virus clearance to alleviate viral infections. As an Active Pharmaceutical Ingredient (API) in the pharmaceutical industry, Favipiravir is used to treat diseases caused by various RNA viruses.
    This report is a detailed and comprehensive analysis for global Favipiravir API market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Favipiravir API market size and forecasts, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2021-2032
    Global Favipiravir API market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2021-2032
    Global Favipiravir API market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2021-2032
    Global Favipiravir API market shares of main players, shipments in revenue ($ Million), sales quantity (Tons), and ASP (US$/Ton), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Favipiravir API
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Favipiravir API market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Chunghwa Chemical Synthesis & Biotech, TODACO, Tagoor Laboratories, Biophore, Lee Pharma, Forewin Pharma, Senova Technology, Zhejiang Hengkang Pharmaceutical, Maithili Life Sciences, Hangzhou HETA Pharm & Chem, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Favipiravir API market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Purity ≥ 98%
    Purity < 98%
    Market segment by Application
    Pharmaceuticals
    Scientific Research
    Others
    Major players covered
    Chunghwa Chemical Synthesis & Biotech
    TODACO
    Tagoor Laboratories
    Biophore
    Lee Pharma
    Forewin Pharma
    Senova Technology
    Zhejiang Hengkang Pharmaceutical
    Maithili Life Sciences
    Hangzhou HETA Pharm & Chem
    Aurore Life Sciences
    Bajaj Healthcare
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Favipiravir API product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Favipiravir API, with price, sales quantity, revenue, and global market share of Favipiravir API from 2021 to 2026.
    Chapter 3, the Favipiravir API competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Favipiravir API breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Favipiravir API market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Favipiravir API.
    Chapter 14 and 15, to describe Favipiravir API sales channel, distributors, customers, research findings and conclusion.

    Buy now